School of Medicine
Showing 1-50 of 411 Results
-
Helen Nadel
Clinical Professor, Radiology - Pediatric Radiology
Current Research and Scholarly InterestsClinical research and scholarly interests include topics in Pediatric Nuclear Medicine to include AI evaluation for scintigraphic quantitation, PET MR evaluation of optimized techniques for use in pediatric patient management
-
Ronjon Nag
Casual - Other Teaching Staff
BioRonjon Nag is an inventor, teacher and entrepreneur. He is an Adjunct Professor in Genetics at the Stanford School of Medicine, becoming a Stanford Distinguished Careers Institute Fellow in 2016. He teaches AI, Genes, Ethics, Longevity Science and Venture Capital. He is a founder and advisor/board member of multiple start-ups and President of the R42 Group, a venture capital firm which invests in, and creates, AI and Longevity companies. As an AI pioneer of smartphones and app stores, his companies have been sold to Apple, BlackBerry, and Motorola. More recently he has worked on the intersection of AI and Biology. He has been awarded the IET Mountbatten Medal by the Institution of Engineering and Technology, the 2021 IEEE-SCV Outstanding Engineer Award, the $1m Verizon Powerful Answers Award, the 2023 COX AI Lifetime Achievement Award, the 2023 MIT Great Dome Award, and is the 2024 Inductee in the Silicon Valley Engineering Hall of Fame. Professor Nag has a Ph.D from Cambridge, an M.S from Massachusetts Institute of Technology and a B.Sc. from Birmingham in the UK. He has numerous interests in the intersection of AI and Healthcare including being CEO of Agemica.ai working on creating a vaccine for aging.
He has many firsts including:
Firsts:
• First laptop with speech recognition built-in (with Apricot, 1984)
• First selling cursive handwriting recognition (with Lexicus, 1991)
• First speech recognition phones (with Lexicus/Motorola, 1996)
• First large-vocabulary Chinese speech recognition (with Lexicus/Motorola, 1996)
• First Chinese predictive text system on a phone (Lexicus/Motorola, 1997)
• First predictive text systems in 40 languages on Motorola phones, (Lexicus/Motorola, 1997)
• First touch screen mobile phone with handwriting recognition (Lexicus/Motorola, 1999)
• First combined mobile search engine and directory (with Cellmania, 2000)
• First private label downloadable operator billable apps store (Cellmania, 2000)
• First BlackBerry Operator Billing apps store (Cellmania,2010)
• First Neural Network Artificial Intelligence System in the Cloud (Ersatz Labs, 2014)
• First Throwable 360 Ball Camera (Bounce Imaging, 2015)
• First Android powered smart light switch (Brightswitch 2017)
• First blood pressure watch with temperature and pulse oximetry add-ons for Back to Work Covid Kit (GTCardio 2019)
• First no code AI life sciences app store (Superbio.ai 2022)
• First proposal for an aging vaccine (Agemica 2023) -
Claude M. Nagamine, DVM, PhD
Associate Professor of Comparative Medicine
On Partial Leave from 02/01/2024 To 08/31/2024Current Research and Scholarly InterestsMouse models to study murine and human infectious diseases. These colloborative studies include dengue virus, zika virus, adeno-associated virus, coxsackie virus, enterovirus 71, enterohepatic helicobacters, campylobacters, and anaplasma.
-
Dhriti Nagar
Postdoctoral Scholar, Neonatal and Developmental Medicine
BioPremature birth is a leading cause of developmental and neuropsychiatric disorders in children. One of the factors causing these defects is lowered levels of available oxygen (hypoxia) in the newborn due to immature lungs. My research focuses on understanding the cellular and molecular mechanisms underlying hypoxia-induced developmental disorders of the nervous system due to preterm birth.
-
Seema Nagpal, MD
Clinical Professor, Neurology & Neurological Sciences
Clinical Professor (By courtesy), NeurosurgeryCurrent Research and Scholarly InterestsI'm a board certified neuro-oncologist who treats both primary brain tumors as well as metastatic disease to the brain and nervous system. My research concentrates on clinical trials for patients with late-stage central nervous system cancer. I have a special interest in leptomeningeal disease, a devastating complication of lung and breast cancers. I collaborate with Stanford scientists to detect this disease earlier, and with our breast and lung oncologists to improve outcomes for patients.
-
Sydney Clara Nagy
Temp - Non-Exempt, Rad/Molecular Imaging Program at Stanford
BioWebsite: https://sydneycnagy.wixsite.com/sydneyclaranagy
IMDb: https://www.imdb.com/name/nm10012799 -
Hetanshi Naik
Associate Professor (Teaching) of Genetics
BioHetanshi Naik is an Associate Professor in the Department of Genetics and the Research Director of the MS Program in Human Genetics and Genetic Counseling. She is a board certified genetic counselor and clinical researcher with clinical expertise in the inborn errors of heme biosynthesis, the Porphyrias, lysosomal storage disorders (LSDs), and pharmacogenomics, and research expertise in clinical trials, patient reported outcomes (PROs), qualitative methods, and study design.
Her research interests include developing and evaluating PROs for genetic disorders and genomics, in particular assessing PROs as outcomes for clinical trials, pharmacogenomics implementation, and genetic counseling education and processes, as well as utilizing digital health technologies to improve clinical care, genetic counseling, patient reporting, trial efficacy, and outcomes. -
Priya Nair
Ph.D. Student in Bioengineering, admitted Autumn 2020
BioI received my Bachelor's degree in Biomedical Engineering with a minor in Industrial Design from Georgia Institute of Technology in 2020. During my time at Georgia Tech, I worked as an undergraduate researcher in Dr. Ajit Yoganathan's Cardiovascular Fluid Mechanics Lab. My project was focused on studying the contribution of foreign materials to thrombosis in transcatheter aortic valves using an in vitro flow loop. Beyond my research interests, I was also actively involved in the Society of Women Engineers, promoting outreach activities and creating mentorship opportunities for women in STEM.
-
Ramesh Nair
Director of Bioinformatics, SCGPM, Genetics
Current Role at StanfordDirector, Bioinformatics
Stanford Center for Genomics and Personalized Medicine (SCGPM)
Bioinformatics-as-a-Service (BaaS)
Genetics Bioinformatics Service Center (GBSC)
Diabetes Genomics Analysis Core (DGAC)
Stanford University School of Medicine -
Bryson Nakamura
Director & Head Sport Scientist - Stanford Baseball Science Core, Orthopaedic Surgery
BioBryson Nakamura, PhD. is the Director & Head Sport Scientist for the Stanford Baseball Science Core. Nakamura will lead baseball sport science research efforts while also supporting the Stanford Baseball team.
Nakamura previously spent six seasons with the Milwaukee Brewers Baseball Club in various sport science and performance roles. In his years with the Brewers, Nakamura established the Integrative Sports Performance department, which aimed to leverage sport science processes and principles to help put the Brewers at the forefront of data-driven player development methods and to enhance and support all functions of baseball operations. In his final year with the club, he was also responsible for overseeing minor league strength and conditioning in his role as the Director of Player Performance.
Prior to joining the Brewers, Nakamura was a sport science intern with the Tampa Bay Rays while completing his doctorate at the University of Oregon in the Bowerman Sports Science Clinic. At Oregon, his primary research focused on gait characteristics of lower-extremity amputees, while his clinical work focused on the assessment of biomechanical and physiological performance factors for high-level distance runners. He graduated with a bachelor’s degree from the University of Puget Sound in Exercise Science where he played baseball and conducted research focused on balance and footwear product design.
Currently, Nakamura is a member of the American Society of Biomechanics, International Society of Biomechanics in Sport, American College of Sports Medicine, and is a founding member and Vice President of Conferences & Meetings for the American Baseball Biomechanics Society. -
Michitaka Nakano
Postdoctoral Scholar, Hematology
BioI am a MD/PhD postdoctoral fellow and medical oncologist with a long-standing interest in translational cancer research. My long-term goal is to be a lab-based physician-scientist and independent academic researcher, translating basic cancer research, and mentoring next-generation scientists. My thesis work in Japan focused on cancer stem cell equilibrium by uniquely applying organoid culture as a method to elucidate cancer stem cell dynamics, which was awarded in Japanese Cancer Association. Along with the development of the field represented by success in T cell checkpoint, my interest gradually shifted to immune oncology while I examined numerous numbers of cancer patients as a medical oncology fellow. My postdoctoral fellowship at Calvin Kuo Lab in Stanford (2019-present) focuses on tumor immune microenvironment. Kuo lab developed a unique 3D air-liquid interface (ALI) organoid system that cultures tumors while preserving their endogenous infiltrating immune cells (T,B ,NK, Myeloid cells). My postdoctoral work will prove the significance of organoids as a translational tool to discover tumor-immune interaction by novel checkpoint inhibitors for immune cells, which can be broadly applicable to basic cancer biology, precision medicine, therapeutics validation and biomarker discovery.
-
Hiromitsu (Hiro) Nakauchi
Professor of Genetics (Stem Cell)
Current Research and Scholarly InterestsTranslation of discoveries in basic research into practical medical applications
-
Yusuke Nakauchi
Instructor, Institute for Stem Cell Biology and Regenerative Medicine
Current Research and Scholarly InterestsFrom 2005 to 2010, my work as a clinical hematology fellow allowed me to experience first-hand how scientific advances that started in a laboratory can transform patients' lives. While many of my patients were cured of their disease with allogeneic hematopoietic stem cell transplantation, underscoring the importance of anti-tumor immunotherapy in eradicating leukemia, I witnessed face-to-face their suffering from the long-term consequence of graft-versus-host disease (GVHD). This experience was ultimately what drove me to engage in research to discover novel therapies. For this reason, I embarked on a Ph.D. program in 2010 to design antibody therapy to (i) target GVHD and (ii) target hematological malignancies. Under the mentorship of Professor Hiromitsu Nakauchi at the University of Tokyo, an international leader in hematopoiesis, I developed allele-specific anti-human leukocyte antigen (HLA) monoclonal antibodies for severe GVHD caused by HLA-mismatched hematopoietic stem cell transplantation (Nakauchi et al., Exp Hematol, 2015). This study was the first to find that anti-HLA antibodies can be used therapeutically against GVHD. That success gave me the motivation and confidence to further my research beyond targeting GVHD to targeting leukemic stem cells through my postdoctoral fellowship in the laboratory of Professor Ravindra Majeti here at Stanford University.
Many people suffer from leukemia each year, but we still don't know how to cure it completely. Recent advances in sequencing technologies have tremendously improved our understanding of the underlying mutations that drive hematologic malignancies. However, the reality is that most of the mutations are not easily "druggable," and the discovery of these mutations has not yet significantly impacted patient outcomes. This is perhaps the most crucial challenge facing a translational cancer researcher like myself. My current research is a major step toward my long-term goal of making personalized medicine a reality for patients with acute myeloid leukemia (AML) and other hematologic malignancies.
Since joining the Majeti lab, I have been targeting the ten-eleven translocation methylcytosine dioxygenase-2 (TET2) mutation, which is aberrant in leukemia at a high rate and has been studied using human-derived cells. TET2 is known to be involved in the clonal expansion of cells, and people with this mutation are more likely to suffer from hematologic malignancies. It is also known to be involved in the development of coronary artery disease, a gene that has attracted much attention in recent studies. In my field, it is an essential gene involved in the abnormal proliferation of hematopoietic stem cells. Focusing on this gene, I mapped TET2-dependent 5hmC, epigenetic and transcriptional programs matched to competitive advantage, myeloid skewing, and reduced erythroid output in TET2-deficient hematopoietic stem and progenitor cells (HSPC). Vitamin C and azacitidine restore the 5hmC landscape and phenotypes in TET2-mutant HSPCs. These findings offer a comprehensive resource for TET-dependent transcriptional regulation of human hematopoiesis and shed light on the potential mechanisms by which TET deficiency contributes to clonal hematopoiesis and malignancies. Of course, these findings would also be of value in understanding the biology of normal hematopoietic stem cells (HSCs) and various other TET2-related cancers.
And from now on, I would like to use the single-cell transplantation techniques mastered in the Majeti lab to study the behavior of normal and aberrant human HSCs using various new methods, ultimately preventing the progression of AML.
In my clinical experience, I have lost many AML patients. With the regret and sadness of losing these patients in my heart, I hope to one day contribute to developing treatments that will fundamentally change how the world treats leukemia. -
Anjali Nambiar
Social Science Research Professional 1, Stanford-Surgery Policy Improvement Research and Education Center
BioAnjali Nambiar, B.S., is a Social Science Research Professional at the Surgery Policy Improvement Research and Education (S-SPIRE) Center. Anjali completed her degree in Biological Sciences at UC Irvine where she was involved in a variety of clinical research projects, including those focused on palliative care access, ultrasound diagnostics, food insecurity, and medical technology. She has also worked with several public health nonprofits to implement new programs at community-based clinics and organizations. At S-SPIRE, she supports ongoing clinical trials by assisting with patient enrollment and facilitating data safety management boards.
-
Shweta S. Namjoshi MD MPH
Clinical Associate Professor, Pediatrics - Gastroenterology
Current Research and Scholarly Interests1. The mission of the International Intestinal Failure Registry (IIFR) is to provide the international intestinal rehabilitation and transplant community with accurate data on the outcomes and course of intestinal failure to support research, quality improvement, and policy development. https://tts.org/irta-registries/irta-ifr
2. NCT05241444 is the first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4^LVFOXP3 in up to 36 evaluable human participants with IPEX and evaluate the impact of the CD4^LVFOXP3 infusion on the disease.
3. Stanford's local Intestinal Failure Registry (SIFR) ensures ongoing assessment and improvement of intestinal failure outcomes and care provided at Stanford in collaboratiton with the Division of Pediatric Surgery. This registry focuses on clinical outcomes and social developmental outcomes for patients with short bowel syndrome, pediatric CODEs, and pseudoobstruction.
